Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension

Wang Zhong; Yue ZhenDong; Zhao HongWei; Wang Lei; Fan ZhenHua; Wu YiFan; Dong ChengBin; Zhang Yu; Liu FuQuan

doi:10.3969/j.issn.1001-5256.2020.09.017

Volume 36 Issue 9

Sep. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(9): 1994-1997

PDF( 335 KB)

Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2020.09.017

Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University

Research funding:

Published Date: 2020-09-20

Abstract

Abstract

Objective To investigate the clinical value of indocyanine green retention rate at 15 minutes( ICG-R15),Child-Turcotte-Pugh( CTP) class,and Model for End-Stage Liver Disease( MELD) score in predicting post-transjugular intrahepatic portosystemic shunt( TIPS) hepatic encephalopathy( HE) in liver cancer patients with portal hypertension. Methods A retrospective analysis was performed for the clinical data of 95 liver cancer patients with portal hypertension who underwent TIPS in Department of Interventional Therapy in Beijing Shijitan Hospital from January 2015 to June 2017,and according to the presence or absence of HE after TIPS,they were divided into HE group with 24 patients and non-HE group with 71 patients. ICG-R15,CTP class,and MELD score were determined for all patients before surgery. The t-test was used for comparison of normally distributed continuous data between two groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test and the Fisher's exact test were used for comparison of categorical data between two groups. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for HE after TIPS,and the receiver operating characteristic( ROC) curve was used to analyze the value of ICG-R15,CTP class,and MELD score in predicting HE. Results The incidence rate of HE was 25. 2%( 24/95) within 12 months after TIPS. The univariate analysis showed that stent location( P = 0. 021),ICG-R15( P = 0. 005),and CTP class( P = 0. 040) were associated with HE after TIPS. The multivariate analysis showed that stent located in the right portal vein( OR = 3. 373,95% CI: 2. 346 ～ 5. 103,P = 0. 010) and ICG-R15 > 30%( OR = 2. 107,95% CI: 1. 331 ～ 3. 212,P = 0. 036) were independent risk factors for HE after TIPS in liver cancer patients with portal hypertension. The ROC curve analysis showed that ICG-R15,MELD score,and CTP class had an area under the ROC curve of 0. 659,0. 638,and 0. 621,respectively,in predicting HE after TIPS. Conclusion ICG-R15 has a certain clinical value in predicting HE after TIPS in liver cancer patients with portal hypertension.
- liver neoplasms,
- indocyanine green,
- hypertension,portal,
- portasystemic shunt,transjugular intrahepatic,
- hepatic encephalopathy

FullText(HTML)

References(19)

References

[1] Cancer minimally invasive therapy professional committee of china cancer association,Asian society for tumor ablation.Minimally invasive and multi-disciplinary comprehensive diagnosis and treatment of hepatocellular carcinoma:2018guangzhou consensus[J]. J Clin Hepatol,2019,35(10):2176-2184.(in Chinese)亚太影像引导下肿瘤微创治疗协会，中国抗癌协会肿瘤微创治疗专业委员会，亚洲肿瘤消融学会．肝细胞癌微创与多学科综合诊疗———2018广州共识[J]．临床肝胆病杂志，2019,35(10):2176-2184.

[2] SANKAR K,MOORE CM. Transjugular intrahepatic portosystemic shunts[J]. JAMA,2017,317(8):880.

[3] ROWLEY MW,CHOI M,CHEN S,et al. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt:Risk factors and outcomes with revision[J].Cardiovasc Intervent Radiol,2018,41(11):1765-1772.

[4] KRAGLUND F,JEPSEN P,AMANAVICIUS N,et al. Longterm effects and complications of the transjugular intrahepatic portosystemic shunt:A single-centre experience[J]. Scand J Gastroenterol,2019,54(7):899-904.

[5] KOKUDO T,HASEGAWA K,AMIKURA K,et al. Assessment of preoperative liver function in patients with hepatocellular carcinoma-The Albumin-Indocyanine Green Evaluation(ALICE)grade[J]. PLo S One,2016,11(7):e0159530.

[6] WANG YY,ZHAO XH,MA L,et al. Comparison of the ability of Child-Pugh score,MELD score,and ICG-R15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma[J]. J Surg Oncol,2018,118(3):440-445.

[7] AZUMI M,SUDA T,TERAI S,et al. Prognostic impact of indocyanine green plasma disappearance rate in hepatocellular carcinoma patients after radiofrequency ablation:A prognostic nomogram study[J]. Intern Med,2017,56(9):1001-1007.

[8] SONG P,INAGAKI Y,WANG Z,et al. High levels of gammaglutamyl transferase and indocyanine green retention rate at 15min as preoperative predictors of tumor recurrence in patients with hepatocellular carcinoma[J]. Medicine(Baltimore),2015,94(21):e810.

[9] LLOVET JM,ZUCMAN-ROSSI J,PIKARSKY E,et al. Hepatocellular carcinoma[J]Nat Rev Dis Primers,2016,2:16018.

[10] International group,Chinese Society of Radiology,Chinese medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol,2017,33(7):1218-1228.(in Chinese)中华医学会放射学分会介入学组．经颈静脉肝内门体分流术专家共识[J]．临床肝胆病杂志，2017,33(7):1218-1228.

[11] ZOU H,YANG X,LI Q L,et al. A comparative study of albumin-bilirubin score with child-pugh score,model for endstage liver disease score and indocyanine green r15 in predicting posthepatectomy liver failure for hepatocellular carcinoma patients[J]. Dig Dis,2018,36(3):236-243.

[12] SIA D,VILLANUEVALL A,FRIEDMAN SL,et al. Liver cancer cell of origin,molecular class,and effects on patient prognosis[J]. Gastroenterology,2017,152(4):745-761.

[13] FERLAY J,SOERJOMATARM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):e359-e386.

[14] MARENOGO A,ROSSO C,BUGIANESI E. Liver cancer:Connections with obesity,fatty liver,and cirrhosis[J]. Annu Rev Med,2016,67:103-117.

[15] MONTAGNESE S,RUSSO FP,AMODIO P,et al. Hepatic encephalopathy 2018:A clinical practice guideline by the Italian Association for the Study of the Liver(AISF)[J]. Dig Liver Dis,2019,51(2):190-205.

[16] HIWATASHIL K,UENO S,SAKODA M,et al. The evaluation of liver function and surgical influence by ICGR15 after chemotherapy for colorectal liver metastases[J]. J Cancer,2016,7(5):595-599.

[17] HE F,DAI S,XIAO Z,et al. Pathological predictors of shunt stenosis and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Biomed Res Int,2016,2016:3681731.

[18] LUO SH,CHU JG,HUANG H,et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J].World J Gastroenterol,2019,25(9):1088-1099.

[19] KAPLAN DE,DAI F,AYTAMAN A,et al. Development and performance of an algorithm to estimate the child-turcottepugh score from a national electronic healthcare database[J]. Clin Gastroenterol Hepatol,2015,13(13):2333-2341. e1-6.

Relative Articles

[1]	Yao Xin, Zhou Hao, Tang ShanHong, Huang Shan, Chen XueLing, Qin JianPing. Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2020, 36(9): 1970-1974. doi: 10.3969/j.issn.1001-5256.2020.09.012
[2]	Huang Shan, Zhou Hao, Chen XueLing, Yao Xin, Tang ShanHong, Yang GuoDong, Qin JianPing. Effect of transjugular intrahepatic portosystemic shunt on the liver and the heart[J]. Journal of Clinical Hepatology, 2020, 36(4): 904-907. doi: 10.3969/j.issn.1001-5256.2020.04.043
[3]	Li Jing, Jiang Yong, Zhang Xu. Efficacy of transjugular intrahepatic portosystemic shunt versus endoscopic cyanoacrylate injection in treatment of gastric variceal bleeding: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(2): 349-353. doi: 10.3969/j.issn.1001-5256.2019.02.021
[4]	Zou SongLong, Xu Ying. Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(1): 201-204. doi: 10.3969/j.issn.1001-5256.2019.01.044
[5]	Yao Xin, Zhou Hao, Tang ShanHong, Xie Min, Huang Shan, Qin JianPing. Stent dysfunction after transjugular intrahepatic portosystemic shunt: Causes and countermeasures[J]. Journal of Clinical Hepatology, 2019, 35(5): 1052-1056. doi: 10.3969/j.issn.1001-5256.2019.05.023
[6]	The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. Journal of Clinical Hepatology, 2019, 35(12): 2694-2699. doi: 10.3969/j.issn.1001-5256.2019.12.010
[7]	He ChuangYe, Chen Hui, Lyu Yong, Xia DongDong, Yu TianLei, Yuan XuLong, Li Kai, Wang ZhengYu, Niu Jing, Bai Wei, Guo WenGang, Tie Jun, Yin ZhanXin, Han GuoHong. Safety and efficacy of flow-reducing stent in treatment of recurrent or persistent hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(8): 1719-1722. doi: 10.3969/j.issn.1001-5256.2019.08.014
[8]	Wang Zhong, Liu FuQuan. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(12): 2824-2827. doi: 10.3969/j.issn.1001-5256.2019.12.040
[9]	Ding ZhiFeng, Yin ShiWu, Zhang GuoBing, Wang MingQuan, Pan ShengQuan. Clinical effect of Viatorr stent versus double-stent technique in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(3): 579-582. doi: 10.3969/j.issn.1001-5256.2018.03.026
[10]	Ding ZhiFeng, Yin ShiWu. Application of Viatorr covered stent in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(5): 1107-1110. doi: 10.3969/j.issn.1001-5256.2018.05.039
[11]	Zhang XinTong, Qi XingShun, Luo JianJun, Guo XiaoZhong. An excerpt of consensus conference on TIPS management: techniques, indications, contraindications (Italy, 2016)[J]. Journal of Clinical Hepatology, 2017, 33(3): 428-431. doi: 10.3969/j.issn.1001-5256.2017.03.005
[12]	Interventional Group, Chinese Society of Radiology, Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2017, 33(7): 1218-1228. doi: 10.3969/j.issn.1001-5256.2017.07.004
[13]	Tuo Lin, Tang ShanHong, Zeng WeiZheng, Wu XiaoLing. Treatment and prevention strategies to complications of transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 354-357. doi: 10.3969/j.issn.1001-5256.2016.02.034
[14]	Zhai YaNan, Li Lei, Yin Liang, Guo QiHong, Lei JunQiang, Guo ShunLin, Zhang ChunYu, Wang HaiJun, Wen XiaoXiao. Role of dual-source CT low-dose whole liver perfusion imaging in evaluating liver blood perfusion after transjugular intrahepatic portosystemic shunt in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(10): 1894-1899. doi: 10.3969/j.issn.1001-5256.2016.10.014
[15]	Niu Meng, Sun Jun, Xu Ke, Zhong HongShan. Retrospects and prospects of transjugular intrahepatic portosystemic shunt in China[J]. Journal of Clinical Hepatology, 2016, 32(2): 230-233. doi: 10.3969/j.issn.1001-5256.2016.02.005
[16]	Ren ShuYao, Chen Hui, Lu: Yong, Wang ZhengYu, Niu Jing, Yin ZhanXin, He ChuangYe, Guo WenGang, Han GuoHong. Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment[J]. Journal of Clinical Hepatology, 2016, 32(6): 1112-1117. doi: 10.3969/j.issn.1001-5256.2016.06.018
[17]	Xu Lu, Xiao Xue, Liu JingQi, Wang Jing, Zhou JingJing, Jiang ChunMeng. Influence of covered stent versus bare stent on long-term efficacy of transjugular intrahepatic portosystemic shunt: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1900-1905. doi: 10.3969/j.issn.1001-5256.2016.10.015
[18]	Wang TingTing, Zhang Feng, ZhuGe YuZheng. Research progress in TIPS shunt dysfunction and recanalization[J]. Journal of Clinical Hepatology, 2015, 31(11): 1921-1923. doi: 10.3969/j.issn.1001-5256.2015.11.041
[19]	Zheng LuanLuan, Han GuoHong, Fan DaiMing. Role of transjugular intrahepatic portosystemic shunt in prevention and treatment of variceal bleeding in liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 687-690. doi: 10.3969/j.issn.1001-5256.2014.07.031
[20]	Tang ShanHong, Qin JianPing, Jiang MingDe, Ceng WeiZheng, Yao Xin, He QianWen, Tang Wen, Gu Ming. Clinical effect and safety of TIPS in treatment of portal hypertension due to alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(2): 145-148. doi: 10.3969/j.issn.1001-5256.2014.02.012

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	张欣，徐怡琼，罗艳，张富军. 吲哚菁绿清除实验的临床应用及研究进展. 上海医学. 2024(05): 314-317 .
2.	李文惠. 分析乳果糖预防肝硬化患者上消化道出血后诱发肝性脑病的疗效. 医学食疗与健康. 2022(13): 29-31+42 .
3.	吴敏，张丽霞. 肠道微生物代谢组学检测在疾病诊疗中的研究进展. 淮海医药. 2022(04): 434-437 .
4.	柴晓哲，朱霞峰，王少峰，骆成林. 白蛋白-胆红素评分联合血氨检测对原发性肝癌切除术后并发肝性脑病的预测价值. 肝脏. 2022(09): 994-998 .
5.	冯其柱，王思雨，张超. 吲哚菁绿荧光显影在困难胆囊腹腔镜胆囊切除术中的应用价值. 临床肝胆病杂志. 2022(11): 2537-2541 . 本站查看
6.	史俪璐，徐慧，陈慧. 双歧杆菌三联活菌胶囊联合乳果糖对经颈静脉肝内门体分流术后肝性脑病的预防效果分析. 中国医学前沿杂志(电子版). 2021(05): 79-83 .
7.	袁巍，李龙鹤，韩晓玉，刘俊，李波，武金才. TIPS术后发生肝性脑病的临床预测模型建立与效能分析. 现代消化及介入诊疗. 2021(07): 874-877 .
8.	路志伟. MRI+多层螺旋CT对于肝性脑病患者诊断准确率的影响分析. 中国实用医药. 2021(26): 21-23 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1668) PDF downloads(118)

Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2020.09.017